13097 Biosimilar BI 695501 demonstrates clinical equivalence to adalimumab reference product in patients with moderate to severe chronic plaque psoriasis through 24 weeks

27381 Phase III, randomized trial comparing clinical outcomes between patients with moderate-to-severe chronic plaque psoriasis receiving adalimumab reference product (RP) continuously vs those who switched between BI 695501 and adalimumab RP

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.574 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB140

Author(s):

Alan Menter ◽

Dorothy McCabe ◽

Benjamin Lang ◽

Jennifer Schaible ◽

Sravan Kumar Eduru

Keyword(s):

Randomized Trial ◽

Clinical Outcomes ◽

Plaque Psoriasis ◽

Reference Product ◽

Phase Iii ◽

Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study

Expert Opinion on Biological Therapy ◽

10.1080/14712598.2021.1851362 ◽

2020 ◽

Vol 21 (1) ◽

pp. 87-96

Author(s):

Alan Menter ◽

Petr Arenberger ◽

Sigrid Balser ◽

Stefan Beissert ◽

Ashley Cauthen ◽

...

Keyword(s):

Plaque Psoriasis ◽

Reference Product ◽

Similar Efficacy ◽

Phase Iii ◽

Severe Chronic Plaque Psoriasis Increases Arterial Stiffness Risk

Skin & Allergy News ◽

10.1016/s0037-6337(08)70558-8 ◽

2008 ◽

Vol 39 (8) ◽

pp. 30

Author(s):

BRUCE JANCIN

Keyword(s):

Arterial Stiffness ◽

Plaque Psoriasis ◽

A Randomized, Double-Blind, Multicenter Study to Compare the Efficacy, Safety, and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Originator Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.1.supp.28 ◽

2017 ◽

Vol 1 ◽

pp. s29

Author(s):

Andrew Blauvelt ◽

Joseph F Fowler, Jr. ◽

Ellen Schuck ◽

Julia Jauch ◽

Heike Woehling ◽

...

Keyword(s):

Multicenter Study ◽

Plaque Psoriasis ◽

Double Blind

Abstract Not Available

Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.1.supp.11 ◽

2017 ◽

Vol 1 ◽

pp. s12

Author(s):

Andrew Blauvelt ◽

Craig Leonardi ◽

Claus Zachariae ◽

Russel Burge ◽

Terri Ridenour ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Health Related

Abstract Not Available

Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis

Case Medical Research ◽

10.31525/ct1-nct03849404 ◽

2019 ◽

Author(s):

Keyword(s):

Plaque Psoriasis ◽

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis

Case Medical Research ◽

10.31525/ct1-nct03922607 ◽

2019 ◽

Author(s):

Keyword(s):

Healthy Volunteers ◽

Plaque Psoriasis ◽

Faculty Opinions recommendation of Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1164520.626285 ◽

2009 ◽

Cited By ~ 1

Author(s):

Joel Gelfand

Keyword(s):

Clinical Trial ◽

Weight Loss ◽

Plaque Psoriasis ◽

Low Dose ◽

Obese Patients ◽

Randomized Controlled ◽

Cyclosporine Therapy

Faculty Opinions recommendation of Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718340215.793493941 ◽

2014 ◽

Author(s):

Kamran Ghoreschi ◽

Sebastian Volc

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Study

AN OPEN-LABELLED RANDOMISED COMPARATIVE EVALUATION OF THERAPEUTIC EFFICACY AND SAFETY OF APREMILAST VERSUS METHOTREXATE IN THE TREATMENT OF PATIENTS WITH CHRONIC PLAQUE PSORIASIS

10.36295/asro.2020.231517 ◽

2020 ◽

Vol 23 (15) ◽

Author(s):

Rathipriyadharshini R ◽

Prem Kumar M ◽

Soundarya S ◽

Srinivasan M.S

Keyword(s):

Plaque Psoriasis ◽

Therapeutic Efficacy ◽

Comparative Evaluation ◽

Efficacy And Safety ◽